ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Merus NV

Merus NV (2GH)

42.20
0.80
(1.93%)
Closed 08 December 8:00AM
Realtime Data

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
42.20
Bid
41.80
Offer
42.80
Volume
0.00
0.00 Day's Range 0.00
21.40 52 Week Range 58.50
Previous Close
41.40
Open
-
Last Trade
Last Trade Time
Average Volume (3m)
127
Financial Volume
-
VWAP
-

2GH Latest News

Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC

Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC Petosemtamab in combination with pembrolizumab in 1L r/m PD-L1 expressing...

Merus gibt FDA-Zulassung von BIZENGRI® (Zenocutuzumab-zbco) für NRG1+-Adenokarzinome der Bauchspeicheldrüse und NRG1+-nicht-kleinzelligen Lungenkrebs (NSCLC) auf der Grundlage von Sicherheits- und Wirksamkeitsdaten aus der eNRGy-Studie bekannt

Merus gibt FDA-Zulassung von BIZENGRI® (Zenocutuzumab-zbco) für NRG1+-Adenokarzinome der Bauchspeicheldrüse und NRG1+-nicht-kleinzelligen Lungenkrebs (NSCLC) auf der Grundlage von Sicherheits- und...

Merus annonce l’autorisation par la FDA de BIZENGRI® (zénocutuzumab-zbco) dans le traitement de l’adénocarcinome pancréatique NRG1+ et du cancer du poumon non à petites cellules (CPNPC) NRG1+, en fonction des données de sécurité et d’efficaci

Merus annonce l’autorisation par la FDA de BIZENGRI® (zénocutuzumab-zbco) dans le traitement de l’adénocarcinome pancréatique NRG1+ et du cancer du poumon non à petites cellules (CPNPC) NRG1+, en...

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy...

Merus und Partner Therapeutics geben Lizenzvereinbarung für die Vermarktung von Zenocutuzumab in den USA bei NRG1-fusionspositivem Krebs bekannt

Merus und Partner Therapeutics geben Lizenzvereinbarung für die Vermarktung von Zenocutuzumab in den USA bei NRG1-fusionspositivem Krebs bekannt UTRECHT, Niederlande, und CAMBRIDGE, Massachusetts...

Merus et Partner Therapeutics annoncent un contrat de licence en vue de la commercialisation aux États-Unis du zenocutuzumab dans le cadre du traitement des cancers à fusion NRG1 positive

Merus et Partner Therapeutics annoncent un contrat de licence en vue de la commercialisation aux États-Unis du zenocutuzumab dans le cadre du traitement des cancers à fusion NRG1 positive UTRECHT...

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 02...

Merus annonce la publication d’un résumé sur le pétosemtamab en tant que traitement de 2e ligne et au-delà pour le CETC r/m lors de l’édition 2024 du Congrès de l’ESMO Asia

Merus annonce la publication d’un résumé sur le pétosemtamab en tant que traitement de 2e ligne et au-delà pour le CETC r/m lors de l’édition 2024 du Congrès de l’ESMO Asia – Les données...

Merus gibt am ESMO-Kongress 2024 in Asien die Veröffentlichung eines Abstracts zur Behandlung von rezidivierenden/metastasierten Kopf- und Halstumoren ab der zweiten Behandlungslinie mit Petosemtamab bekannt

Merus gibt am ESMO-Kongress 2024 in Asien die Veröffentlichung eines Abstracts zur Behandlung von rezidivierenden/metastasierten Kopf- und Halstumoren ab der zweiten Behandlungslinie mit...

Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024

Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024 – Petosemtamab 1500 mg monotherapy phase 2 interim data continues to...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-1-2.3148148148143.2474319244.19451697DE
4-7.8-15.65051.540.411744.74603537DE
12-3-6.6371681415945.251.540.412747.17167127DE
26-6-12.448132780148.257.540.415948.57608533DE
5219.283.47826086962358.521.39999917344.34418355DE
15618.477.310924369723.858.51916742.00023485DE
26018.477.310924369723.858.51916742.00023485DE

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
TE9Teco 2030 ASA
0.0592 €
(65.36%)
2.11M
A6NAsana Inc
21.00 €
(43.84%)
19.08k
NL8Genesis Ai Corp
0.0214 €
(40.79%)
13.33k
RQ0DWave Quantum Inc
4.814 €
(34.92%)
1.15M
K8DWellfield Technologies Inc
0.0342 €
(34.65%)
30.8k
AXIAtos SE
0.0028 €
(-98.58%)
1.59B
M0YNMynaric AG
1.40 €
(-72.66%)
303.13k
W47Grid Battery Metals Inc
0.0115 €
(-39.47%)
7
47GAGo Metals Corp
0.0202 €
(-36.88%)
3.44k
4APApollo Minerals Ltd
0.0055 €
(-35.29%)
270.7k
AXIAtos SE
0.0028 €
(-98.58%)
1.59B
D7GNel ASA
0.2625 €
(-1.69%)
4.24M
LK1Lake Resources
0.029 €
(-6.75%)
2.32M
TUI1Tui AG
8.40 €
(1.11%)
2.17M
TE9Teco 2030 ASA
0.0592 €
(65.36%)
2.11M

Discussion

View Full Feed
Lime Time Lime Time 5 minutes ago
.0001 forever. Keeps diluting shares.

Nothing here.
PSRU
BDEZ BDEZ 6 minutes ago
Saw that yesterday, thanks
SilkRoad SilkRoad 6 minutes ago
Hey KBLB Kongs, watch the video, like, comment, and subscribe to let the YouTube algorithms know you appreciate the work the entire Kraig Biocraft Laboratories team did in putting together this video for us. Kim and the team look happy, energized, and ready to bring spidersilk to the Global market
KBLB
arizona1 arizona1 8 minutes ago
We are stuck in a news cycle in which Trump is making mind-numbing nominations, and his henchmen are making ludicrous proposals to eliminate $2 trillion from the budget. This state of affairs will stretch into early January. It is not a good place to be because we are in a partial state of suspended
dinogreeves dinogreeves 9 minutes ago
IHUB posters and flippers don't control price action. This is the only pure play in this field.

"Chinese researchers are using D-Wave QC systems to break data encryptions like RSA. D-Wave is the only player using Annealing methods, all others all use Gate approach. They have zero
QBTS
dedugan dedugan 9 minutes ago
2 grams of GBM is about the size of an average blueberry, per Chat GPT.
NWBO
Hercules1 Hercules1 10 minutes ago
there is massive, endless, unremitting chatter/buzz about this stock on social media.

lot of people--especially the top traders--are talking about it.
HMBL
Hercules1 Hercules1 11 minutes ago
i think this breaks .005 on monday with ease.
HMBL
Longstrongsilver Longstrongsilver 13 minutes ago
I understand the sentiment , but you always have to count the restricted shares lol. Restricted or not they are still part of the MC. Just buy the dips fool
AZRH
gitreal gitreal 13 minutes ago
I do follow along with what the company and it's management are saying.....and it is increasingly outrageous hype.



PGMs..... nonsense. Rhodium at 750 ppm, sheer BS. If they have PGMs and rhodium at crazy high values......why not prove it? Hmmm?

An
SDRC
dinogreeves dinogreeves 14 minutes ago
I agree with that sentiment, but most definitely we will tap dance with 60 dollars by Tuesday.
SMCI
delerious1 delerious1 14 minutes ago
Shelly....I have no other way to contact you.
I have been 2 weeks without violating the rules here.
Could you reverse the sanctions on me now....it has been over 2 years on some?
I will remove this post if you don't see it soon.

Delerious1

@IH Admi
Hercules1 Hercules1 15 minutes ago
https://x.com/Wonder_Women777/status/1865544621146661364
HMBL
Hercules1 Hercules1 15 minutes ago
https://x.com/a17zBTC/status/1865535328783655078
HMBL
BurgerKing82 BurgerKing82 16 minutes ago
Recent action looks good?
CBGL
AJH92 AJH92 16 minutes ago
$PSRU Overview - Updated December 7, 2024
----------------------------------------------------------
$PSRU Portfolio of Companies / Partnerships

African Cinema Content In USA
America's Next Investment (ANI)
Cote Quest Distribution
Franchise X Enterta
DTC MDCN PSRU
sortagreen sortagreen 16 minutes ago
https://scontent-lga3-3.xx.fbcdn.net/v/t39.30808-6/469555526_2724858364368845_4058582826716105542_n.jpg?_nc_cat=104&ccb=1-7&_nc_sid=aa7b47&_nc_ohc=Z3zTK3fEu6sQ7kNvgG_Lcat&_nc_zt=23&_nc_ht=scontent-lga3-3.xx&_nc_gid=ARJk3Cwc0NI8xIh2T8QLRKU&oh=00_AYAyxNwC9r4oHTmAq72yYOwtyKAmNBiopuM1l4YARbP3kg&oe=675A9
Filterthenoise Filterthenoise 19 minutes ago
Did they strike a deal for INQR too? That would suck for the pigs 🎅
INQR
CC88Trade CC88Trade 19 minutes ago
Stop taking individual investors words as propaganda truth. Actually follow along with the company…. You make all the heresay as if the company says that themselves. Get a life
SDRC
gitreal gitreal 20 minutes ago
Neither. NBRI is a dilution scam...not a real mining company.
NBRI
floblu14 floblu14 20 minutes ago
FWIW - although this might be standard procedure - and, these ideas could be overly exaggerated - however -

Not to second guess or find a needle in a haystack but noticed that ENTA will be presenting SLIDES this Monday at 8:30 to coincide with their presentation -
https://edg
ENTA
The Danish Dude The Danish Dude 20 minutes ago
exwannabe: WRONG ... AGAIN!

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175493730

Though $1 (on the way down, $4 on the way up) is an issue

And that is not true, and you know it. $4 is for INITIAL listing.NWBO made a voluntary delist an
NWBO
ChartTRACKER ChartTRACKER 20 minutes ago
$GRLT : What happened to this ticker?
I've been away for a while.
I thought merger was complete with the $40M deal 🧐
GRLT

Your Recent History

Delayed Upgrade Clock